HPLC法测定盐酸表阿霉素-索拉非尼PLGA栓塞微球的载药量和包封产率Δ

2017-08-14 22:33:04刘斌斌黄珊珊朱益雷罗晓健江西中医药大学药学院南昌330006中药固体制剂制造技术国家工程研究中心南昌330006
中国药房 2017年21期
关键词:索拉非尼

刘斌斌,简 晖,黄珊珊,刘 微,朱益雷,罗晓健,李 翔#(.江西中医药大学药学院,南昌330006;.中药固体制剂制造技术国家工程研究中心,南昌 330006)

HPLC法测定盐酸表阿霉素-索拉非尼PLGA栓塞微球的载药量和包封产率Δ

刘斌斌1*,简 晖1,2,黄珊珊1,刘 微2,朱益雷1,罗晓健1,2,李 翔1,2#(1.江西中医药大学药学院,南昌330006;2.中药固体制剂制造技术国家工程研究中心,南昌 330006)

目的:建立测定盐酸表阿霉素-索拉非尼聚乳酸-羟基乙酸聚合物(PLGA)栓塞微球载药量和包封产率的方法。方法:采用高效液相色谱法测定该制剂中盐酸表阿霉素和索拉非尼的含量,再通过公式计算载药量和包封产率。色谱柱为Phenomenex Luna 5u C8(2)100A,流动相为甲醇-[水(含0.05%三氟乙酸和0.14%十二烷基硫酸钠)](75∶25,V/V),流速为1.0 mL/min,检测波长为252 nm,柱温为25℃,进样量为10 μL。结果:盐酸表阿霉素和索拉非尼检测质量浓度线性范围分别为2.020~101.00 μg/mL(r=0.999 8)、2.048~102.40 μg/mL(r=0.999 7);定量限分别为3.297 0、2.546 8 μg/mL;检测限分别为0.989 1、0.764 1 μg/mL;精密度、稳定性、重复性试验的RSD<2.0%;回收率分别为96.41%~101.80%(RSD=1.64%,n=9)、99.46%~101.45%(RSD=0.70%,n=9)。3批样品中两种成分的载药量≥1.17%,包封产率≥58%。结论:该方法操作简单、结果准确,可用于测定盐酸表阿霉素-索拉非尼PLGA栓塞微球的载药量和包封产率。

盐酸表阿霉素;索拉非尼;聚乳酸-羟基乙酸聚合物;栓塞微球;高效液相色谱法;载药量;包封产率

ABSTRACTOBJECTIVE:To establish a method for the determination of drug loading and encapsulation efficiency of Epirubicin hydrochloride-sorafenib-loaded Polylactic Acid-glycolic Acid Polymer(PLGA)embolic microspheres.METHODS:HPLC method was adopted to determine the contents of epirubicin hydrochloride and sorafenib in the preparation,and then drug loading and encapsulation efficiency were calculated by formula.The determination was performed on Phenomenex Luna 5u C8(2)100A column with mobile phase consisted of methanol-water(containing 0.05%trifluoroacetic acid and 0.14%dium dodecyl sulfate)(75∶25,V/V)at the flow rate of 1.0 mL/min.The detection wavelength was set at 252 nm,and the column temperature was maintained at 25℃.The injection volume was 10 μL.RESULTS:The linear ranges were 2.020-101.00 μg/mL for epirubicin hydrochloride(r=0.999 8)and 2.048-102.40 μg/mL for sorafenib(r=0.999 7),respectively.The limits of quantification were 3.297 0,2.546 8 μg/ mL,respectively.The detection limits were 0.989 1,0.764 1 μg/mL,respectively.RSDs of precision,stability and repeatability tests were all less than 2.0%.The recoveries were 96.41%-101.80%(RSD=1.64%,n=9),99.46%-101.45%(RSD=0.70%,n=9),respectively.Drug loading of two components in 3 batches of samples were no lower than 1.17%,encapsulation efficiency no lower than 58%.CONCLUSIONS:The method is simple,accurate,can be used to determine drug loading and encapsulation efficiency of Epirubicin hydrochloride-sorafenib PLGA embolic microspheres.

KEYWORDSEpirubicin hydrochloride;Sorafenib;PLGA;Embolic microspheres;HPLC;Drug loading;Encapsulation efficiency

原发性肝癌(Primary hepatocellular carcinoma,PHC)是最常见的恶性肿瘤之一,在我国的发病率和致死率均占全球总发病率和致死率的一半以上[1]。载药栓塞微球是一种用于治疗原发性肝癌中、晚期患者的新型药物递送系统,其联合了肝动脉栓塞和局部化疗两种治疗技术优势,越来越受到国内外研究者的关注[2-3]。……

登录APP查看全文

猜你喜欢
索拉非尼
大豆异黄酮协同索拉非尼对宫颈癌Hela细胞增殖、迁移的影响及机制
肝细胞癌中索拉非尼耐药性机制的研究进展
原发性肝癌治疗中索拉非尼耐药发生机制的研究进展
肿瘤(2021年6期)2021-04-17 13:02:18
非编码RNA在索拉非尼治疗肝细胞癌耐药中的作用机制
索拉非尼治疗肝移植后肝细胞癌复发的单中心回顾性分析
NRF2/PI3K通路介导肝癌细胞SMMC-7721出现索拉非尼耐药的机制研究
肝脏(2020年9期)2020-10-22 08:02:10
敲减缺氧诱导因子-2α联合索拉非尼对肾癌细胞促凋亡作用的研究*
索拉非尼治疗原发性肝癌的应用进展研究
索拉非尼治疗肾细胞癌和肝细胞癌患者相关毒副作用探讨
河北医学(2016年8期)2016-09-15 07:50:42
索拉非尼治疗晚期肾癌期间引发高血压的分析